<DOC>
	<DOC>NCT00637871</DOC>
	<brief_summary>This study looks at the relationship in the dose of nolvadex and the incidence of gynaecomastia and also Prostate Specific Antigen (PSA) inhibition when co-administered with Casodex. The aim of the study is to assess the optimal dose of nolvadex which will reduce the breast tissue adverse effects without reducing the efficacy of Casodex.</brief_summary>
	<brief_title>Casodex - Nolvadex Combination</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Gynecomastia</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<criteria>Subjects with adenocarcinoma of the prostate gland but with no evidence of distant metastasis. The stage of disease should be T1T4, any N, M0 confirmed histologically or cytologically Subjects in need of immediate hormonal therapy. PSA equal or above 4 ng/ml Presence of gynaecomastia and/or breast pain at screening visit Any previous endocrine therapy for prostate cancer other than neoadjuvant LHRH therapy prior to primary therapy of curative intent. Current use, or within the previous 6 months, of any medication known to have a high risk of causing gynaecomastia . Previous mastectomy or radiation to chest wall</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Casodex</keyword>
	<keyword>bicalutamide</keyword>
	<keyword>Tamoxifen</keyword>
	<keyword>Gynaecomastia</keyword>
	<keyword>Prostate Cancer</keyword>
</DOC>